Literature DB >> 33288523

Calculation of an Apical Efflux Ratio from P-Glycoprotein (P-gp) In Vitro Transport Experiments Shows an Improved Correlation with In Vivo Cerebrospinal Fluid Measurements in Rats: Impact on P-gp Screening and Compound Optimization.

Holger Fischer1, Claudia Senn2, Mohammed Ullah2, Carina Cantrill2, Franz Schuler2, Li Yu2.   

Abstract

P-glycoprotein (P-gp) is a major blood-brain barrier (BBB) efflux transporter. In vitro approaches, including bidirectional efflux ratio (ER), are used to measure P-gp-mediated transport, but findings can be inconsistent across models. We propose a novel, more physiologically relevant, in vitro model: unidirectional apical efflux ratio (AP-ER)-a ratio of permeability rates at the apical side of the BBB with and without P-gp inhibitor. To test our approach, ER and AP-ER were calculated for 3227 structurally diverse compounds in porcine kidney epithelial cells (LLC-PK1) overexpressing human or mouse P-gp and classified based on their passive transcellular P-gp permeability or charged properties. In vivo rat infusion studies were performed for selected compounds with high ER but low AP-ER. One-third of the 3227 compounds had bidirectional ER that was much higher than AP-ER; very few had AP-ER higher than ER. Compounds with a large difference between AP-ER and ER were typically basic compounds with low-to-medium passive permeability and high lipophilicity and/or amphiphilicity, leading to strong membrane binding. Outcomes in the human model were similar to those in mice, suggesting AP-ER/ER ratios may be conserved for at least two species. AP-ER predicted measured cerebrospinal fluid (CSF) concentration better than ER for the five compounds tested in our in vivo rat infusion studies. We report superior estimations of the CSF concentrations of the compounds when based on less resource-intensive AP-ER versus classic ER. Better understanding of the properties leading to high P-gp-mediated efflux in vivo could support more efficient brain-penetrant compound screening and optimization. SIGNIFICANCE STATEMENT: To address inconsistencies associated with the historical, bidirectional efflux ratio (ER) calculation of P-glycoprotein-mediated transport, we propose to use the novel, more physiologically relevant, unidirectional apical efflux ratio (AP-ER) model. In vitro experiments suggested that compounds with strong membrane binding showed the largest difference between AP-ER and ER, and in vivo infusion studies showed that AP-ER predicted cerebrospinal fluid concentrations of compounds better than ER; outcomes in the human model were similar to those in mice.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2020        PMID: 33288523     DOI: 10.1124/jpet.120.000158

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development.

Authors:  Irena Loryan; Andreas Reichel; Bo Feng; Christoffer Bundgaard; Christopher Shaffer; Cory Kalvass; Dallas Bednarczyk; Denise Morrison; Dominique Lesuisse; Edmund Hoppe; Georg C Terstappen; Holger Fischer; Li Di; Nicola Colclough; Scott Summerfield; Stephen T Buckley; Tristan S Maurer; Markus Fridén
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

Review 2.  In Vitro Models of the Blood-Cerebrospinal Fluid Barrier and Their Applications in the Development and Research of (Neuro)Pharmaceuticals.

Authors:  Fatemeh Dabbagh; Horst Schroten; Christian Schwerk
Journal:  Pharmaceutics       Date:  2022-08-18       Impact factor: 6.525

3.  Similarities and differences in the localization, trafficking, and function of P-glycoprotein in MDR1-EGFP-transduced rat versus human brain capillary endothelial cell lines.

Authors:  Birthe Gericke; Saskia Borsdorf; Inka Wienböker; Andreas Noack; Sandra Noack; Wolfgang Löscher
Journal:  Fluids Barriers CNS       Date:  2021-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.